• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

PCSK9 inhibitor significantly reduces the risk of cardiovascular events: The FOURIER trial

byAndrew Cheung, MD MBAandJames Roebker
May 11, 2022
in General Medicine Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In addition to significantly lowering levels of low density lipoprotein cholesterol (LDL-C), evolocumab reduced the composite risk of cardiovascular events in atherosclerotic patients on optimal statin therapy without a significant increase in adverse effects.

2. As individual endpoints, evolocumab did not significantly reduce the rate of either cardiovascular or all-cause mortality relative to placebo.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Through a novel mechanism of decreased LDL-receptor recycling and increased LDL-C clearance, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have demonstrated powerful and synergistic reductions in LDL-C in conjunction with statin therapy. Yet, no large scale studies have evaluated the efficacy of PCSK9 inhibitors in the prevention of cardiovascular outcomes. This trial evaluated the efficacy of evolocumab, a fully human monoclonal antibody against PCSK9, in reducing cardiovascular outcomes in patients on optimal statin therapy. A significant reduction was found in both the primary (a composite of death, MI, stroke, unstable angina hospitalization, and coronary revascularization) and secondary (death, MI, or stroke) endpoints without an associated increase in adverse events. However, no reduction in cardiovascular or all-cause mortality was found in the analysis of individual outcomes. Given the high cost and unclear mortality benefit, the use of PCSK9 inhibitors will likely remain relegated to select high-risk patients.

This was a parallel, double-blinded trial that enrolled a large number of patients with stable atherosclerotic cardiovascular disease and provided the first evidence for the clinical value of PCSK9 inhibitors. While no direct reduction in all-cause death was found, the data supports both the benefit of reducing LDL-C to unprecedented low levels. The major limitation of this study was the short duration of follow-up.

Click to read the study, published in NEJM

Relevant Reading: Efficacy and safety of evolocumab in reducing lipids and cardiovascular events

RELATED REPORTS

Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events

Improved mortality rates for myocardial infarction, stroke, and pulmonary embolism in patients receiving dialysis between 1998 to 2015

Ophthalmologic procedures are not associated with increased risk for acute myocardial infarction

In-Depth [randomized controlled trial]: This multinational study randomized 27,564 patients with established cardiovascular atherosclerotic disease to treatment with evolocumab (n = 13,784) or matching placebo (n = 13,780) in a 1:1 ratio. All patients had LDL-C of 70 mg/dL (median 92 mg/dL) or non-HDL-C levels of 100 mg/dL and were on high-intensity (69.3%) or moderate-intensity (30.4%) statin therapy at baseline. Median duration of follow-up was 26 months. The primary end point was major cardiovascular events, defined as the composite of cardiovascular death, MI, stroke, unstable angina hospitalization, or coronary revascularization. The secondary end point was the composite of cardiovascular death, MI, or stroke. Adverse events were collected to assess safety.

At 48 weeks, the mean reduction in LDL-C with evolocumab compared to placebo was 59% (95%CI 58 to 60; p < 0.001), with an absolute reduction of 56 mg/dL (95%CI 55 to 57). This reduction was sustained over time. The primary endpoint occurred in 1344 patients (9.8%) with evolocumab group compared to 1593 patients (11.3%) in placebo (HR 0.85; 95%CI, 0.79 to 0.92; p < 0.001). The risk reduction in the primary endpoint increased over time (12% in the first year to 19% beyond the first year). The secondary endpoint occurred in 816 (5.9%) with evolocumab compared to 1013 (7.4%) with placebo (HR 0.80; 95%CI 0.73 to 0.88; p < 0.001). Regarding individual outcomes, there was a 21 to 27% risk reduction in MI, stroke, and coronary revascularization. No significant difference in cardiovascular or all-cause mortality was reported. All data was consistent across major demographic subgroups and quartiles of baseline LDL-C levels. Except for mild injection site reactions (2.1% vs. 1.6% with placebo), no significant difference in adverse events – including new-onset diabetes, antibody development, or neurocognitive adverse events – were associated with evolocumab.

Image: CC/Wiki

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: acute coronary syndromesLDLmyocardial infarctionpcsk9
Previous Post

Evidence-based interventions for pediatric asthma successfully adapted for community health centers

Next Post

Antibiotics often overprescribed in elderly patients

RelatedReports

FDA-approved weight loss medications associated with weight loss at one year
Cardiology

Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events

May 25, 2022
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Improved mortality rates for myocardial infarction, stroke, and pulmonary embolism in patients receiving dialysis between 1998 to 2015

April 22, 2022
Nonpowder gun-related pediatric eye injuries on the rise
Cardiology

Ophthalmologic procedures are not associated with increased risk for acute myocardial infarction

April 22, 2022
30-Day mortality decreased in UK pediatric cardiac surgery from 2000-2010
Cardiology

Clinically important troponin I threshold for mortality after cardiac surgery

March 8, 2022
Next Post
Use of plant-based therapies and menopausal symptoms

Antibiotics often overprescribed in elderly patients

USPSTF finds insufficient evidence for screening for iron deficiency anemia during pregnancy

Hepatitis C on the rise among reproductive-aged women

Trends in US counties cause-specific mortality rates

Geographic disparities in life expectancy across US counties may be due to socioeconomic, race, and behavioral factors

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Methamphetamine use associated with cardiovascular disease in hospitalized patients
  • Management of uncomplicated urinary tract infections amongst women in the United States Military Health System highly concordant with guidelines
  • Gout flares associated with a transient increase in subsequent risk of cardiovascular events
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.